Autism spectrum disorder pharmacotherapy options widen past irritability indications
Risperidone and aripiprazole maturity for ASD-associated irritability, emerging mechanism-targeted programs for core symptoms, and integrated multidisciplinary care models are reshaping ASD pharmacotherapy.
Autism spectrum disorder pharmacotherapy has been limited to risperidone and aripiprazole for ASD-associated irritability and aggression. Emerging mechanism-targeted programs for ASD core symptoms (vasopressin pathway, oxytocin pathway, GABA pathway, others) are reading out in late-stage trials, and integrated multidisciplinary care models (psychiatry with developmental paediatrics with applied behaviour analysis) are formalising. The infrastructure question (specialty access for ASD diagnosis and care) bounds commercial reach.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.